Theravance Biopharma (TBPH) Non-Current Receivables (2017 - 2020)

Theravance Biopharma (TBPH) has 4 years of Non-Current Receivables data on file, last reported at $4.0 million in Q2 2020.

• Quarterly Non-Current Receivables rose 7.88% year-over-year to $4.0 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $4.0 million (up 7.88% YoY) and the FY2019 annual result came in at $3.7 million, changed N/A from the prior year.
• Non-Current Receivables was little changed at $4.0 million in Q2 2020 per TBPH's latest filing, from $4.0 million in the prior quarter.
• Across five years, Non-Current Receivables topped out at $8.2 million in Q4 2017 and bottomed at $3.1 million in Q3 2018.
• The 4-year median for Non-Current Receivables is $3.7 million (2019), against an average of $4.5 million.
• The widest annual swing landed in 2018, when Non-Current Receivables sank 61.2%; it then grew 17.56% in 2019.
• Tracing TBPH's Non-Current Receivables over 4 years: stood at $8.2 million in 2017, then tumbled by 61.78% to $3.1 million in 2018, then increased by 17.6% to $3.7 million in 2019, then climbed by 8.26% to $4.0 million in 2020.
• Per Business Quant, the three latest TBPH Non-Current Receivables figures stand at $4.0 million (Q2 2020), $4.0 million (Q1 2020), and $3.7 million (Q4 2019).

Peer Comparison